tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Replimune Group (REPL) and Intercept Pharma (ICPT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Rocket Pharmaceuticals (RCKTResearch Report), Replimune Group (REPLResearch Report) and Intercept Pharma (ICPTResearch Report).

Rocket Pharmaceuticals (RCKT)

In a report released today, Steven Seedhouse from Raymond James maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $34.00. The company’s shares closed last Friday at $15.96.

According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 4.3% and a 41.8% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Arcturus Therapeutics, and Intellia Therapeutics.

Rocket Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $57.71, representing a 300.2% upside. In a report issued on September 20, SVB Securities also initiated coverage with a Buy rating on the stock.

See the top stocks recommended by analysts >>

Replimune Group (REPL)

SVB Securities analyst Jonathan Chang maintained a Buy rating on Replimune Group today and set a price target of $30.00. The company’s shares closed last Friday at $17.27.

According to TipRanks.com, Chang ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -15.9% and a 22.6% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Bicycle Therapeutics.

Currently, the analyst consensus on Replimune Group is a Strong Buy with an average price target of $41.50.

Intercept Pharma (ICPT)

In a report released today, Thomas Smith from SVB Securities maintained a Hold rating on Intercept Pharma, with a price target of $17.00. The company’s shares closed last Friday at $13.95.

According to TipRanks.com, Smith has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.3% and a 30.3% success rate. Smith covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Connect Biopharma Holdings, and Madrigal Pharmaceuticals.

Currently, the analyst consensus on Intercept Pharma is a Moderate Buy with an average price target of $25.33, implying a 70.0% upside from current levels. In a report issued on September 21, JMP Securities also reiterated a Hold rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RCKT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles